$AVDL
AVADEL PHARMACEUTICALS PLC Stock $avdl

$avdl Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000101247723000012 Filed on May 04, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$1.496M	$0.00	$0.00
YoY Change
Cost Of Revenue	$36.00K	$0.00
YoY Change
Gross Profit	$1.460M	$0.00
YoY Change
Gross Profit Margin	97.59%
Selling, General & Admin	$46.78M	$24.47M	$21.64M
YoY Change	114.54%	13.09%	96.47%
% of Gross Profit	3203.97%
Research & Development	$4.223M	$3.830M	$6.991M
YoY Change	-7.0%	-45.22%	81.49%
% of Gross Profit	289.25%
Depreciation & Amortization	$601.0K	$588.0K	$259.0K
YoY Change	143.32%	127.03%	17.73%
% of Gross Profit	41.16%
Operating Expenses	$51.00M	$28.30M	$28.63M
YoY Change	93.59%	-1.15%	92.59%
Operating Profit	-$49.54M	-$28.30M	-$28.63M
YoY Change	65.48%	-1.15%	93.28%
Interest Expense	-$2.295M	-$3.259M	-$2.017M
YoY Change	-34.54%	61.58%	4.51%
% of Operating Profit
Other Income/Expense, Net	$623.0K	$193.0K	-$104.0K
YoY Change	224.48%	-285.58%
Pretax Income	-$64.34M	-$31.36M	-$30.75M
YoY Change	93.5%	2.01%	91.55%
Income Tax	$90.00K	-$580.0K	-$4.323M
% Of Pretax Income
Net Earnings	-$64.43M	-$30.78M	-$26.42M
YoY Change	1.56%	16.5%	96.53%
Net Earnings / Revenue	-4306.95%
Basic Earnings Per Share	-$0.83	-$0.48	-$0.45
Diluted Earnings Per Share	-$0.83	-$0.48	-$0.45
COMMON SHARES
Basic Shares Outstanding	76.77M shares	64.48M shares	58.82M shares
Diluted Shares Outstanding	77.25M shares	63.89M shares	58.82M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$160.5M	$100.9M	$123.5M
YoY Change	54.16%	-18.27%	-40.2%
Cash & Equivalents	$49.99M	$83.39M	$60.87M
Short-Term Investments	$110.5M	$17.53M	$62.61M
Other Short-Term Assets	$6.463M	$542.0K	$156.0K
YoY Change	3083.74%	247.44%	4.7%
Inventory	$1.439M
Prepaid Expenses	$5.716M	$5.384M	$5.317M
Receivables	$1.775M	$269.0K	$278.0K
Other Receivables	$1.043M	$2.352M	$31.51M
Total Short-Term Assets	$171.2M	$109.5M	$160.7M
YoY Change	36.21%	-31.9%	-33.66%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.950M	$782.0K	$268.0K
YoY Change	673.81%	191.79%	-22.09%
Goodwill	$16.84M	$16.84M	$16.84M
YoY Change	0.0%	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$10.54M	$10.93M	$39.64M
YoY Change	-10.45%	-72.42%	43.0%
Total Long-Term Assets	$29.75M	$31.27M	$60.39M
YoY Change	-7.69%	-48.22%	19.28%
TOTAL ASSETS
Total Short-Term Assets	$171.2M	$109.5M	$160.7M
Total Long-Term Assets	$29.75M	$31.27M	$60.39M
Total Assets	$201.0M	$140.7M	$221.1M
YoY Change	27.25%	-36.35%	-24.51%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$11.79M	$10.02M	$6.048M
YoY Change	61.05%	65.72%	114.16%
Accrued Expenses	$18.59M	$7.683M	$9.432M
YoY Change	92.14%	-18.54%	119.5%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$20.85M	$20.52M	$26.18M
YoY Change	-20.54%	-21.65%
Total Short-Term Liabilities	$51.50M	$79.36M	$44.02M
YoY Change	11.44%	80.27%	382.71%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$93.14M	$116.5M
YoY Change	-100.0%	-20.07%	-17.63%
Other Long-Term Liabilities	$6.282M	$5.767M	$3.847M
YoY Change	9.9%	49.91%	-7.05%
Total Long-Term Liabilities	$6.282M	$98.91M	$120.4M
YoY Change	-94.48%	-17.83%	-17.33%
TOTAL LIABILITIES
Total Short-Term Liabilities	$51.50M	$79.36M	$44.02M
Total Long-Term Liabilities	$6.282M	$98.91M	$120.4M
Total Liabilities	$57.78M	$178.9M	$165.9M
YoY Change	-64.17%	7.84%	6.05%
SHAREHOLDERS EQUITY
Retained Earnings	-$680.4M	-$616.0M	-$474.2M
YoY Change	26.56%	29.91%	23.53%
Common Stock	$849.5M	$603.9M	$554.4M
YoY Change	51.53%	8.91%	2.17%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$143.2M	-$38.17M	$55.23M
YoY Change
Total Liabilities & Shareholders Equity	$201.0M	$140.7M	$221.1M
YoY Change	27.25%	-36.35%	-24.51%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$64.43M	-$30.78M	-$26.42M
YoY Change	1.56%	16.5%	96.53%
Depreciation, Depletion And Amortization	$601.0K	$588.0K	$259.0K
YoY Change	143.32%	127.03%	17.73%
Cash From Operating Activities	-$32.02M	-$30.23M	-$34.05M
YoY Change	127.27%	-11.2%	45.41%
INVESTING ACTIVITIES
Capital Expenditures			$0.00
YoY Change			-100.0%
Acquisitions
YoY Change
Other Investing Activities	-$92.91M	$5.066M	$42.25M
YoY Change	-871.15%	-88.01%	276.57%
Cash From Investing Activities	-$92.91M	$5.066M	$42.25M
YoY Change	-871.15%	-88.01%	277.54%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	91.54M	$34.44M	$2.009M
YoY Change	-2005.98%	1614.39%	1248.32%
NET CHANGE
Cash From Operating Activities	-32.02M	-$30.23M	-$34.05M
Cash From Investing Activities	-92.91M	$5.066M	$42.25M
Cash From Financing Activities	91.54M	$34.44M	$2.009M
Net Change In Cash	-33.39M	$9.410M	$10.17M
YoY Change	387.76%	-7.43%	-181.0%
FREE CASH FLOW
Cash From Operating Activities	-$32.02M	-$30.23M	-$34.05M
Capital Expenditures			$0.00
Free Cash Flow			-$34.05M
YoY Change			45.25%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001012477
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	No Trading Symbol Flag NoTradingSymbolFlag	true
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-37977
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	AVADEL PHARMACEUTICALS PLC
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	L2
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1341933
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	10 Earlsfort Terrace
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Dublin 2
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	D02 T380
CY2023Q1	dei	Entity Address Country EntityAddressCountry	IE
CY2023Q1	dei	Country Region CountryRegion	353
CY2023Q1	dei	City Area Code CityAreaCode	1
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	901-5201
CY2023Q1	dei	Security12b Title Security12bTitle	Ordinary Shares, nominal value $0.01 per share**
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	76768391	shares
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3830000	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6991000	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	24468000	usd
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	21635000	usd
CY2023Q1	us-gaap	Costs And Expenses CostsAndExpenses	28298000	usd
CY2022Q1	us-gaap	Costs And Expenses CostsAndExpenses	28626000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-28298000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-28626000	usd
CY2023Q1	us-gaap	Investment Income Net InvestmentIncomeNet	193000	usd
CY2022Q1	us-gaap	Investment Income Net InvestmentIncomeNet	-104000	usd
CY2023Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	3259000	usd
CY2022Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	2017000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-31364000	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-30747000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-580000	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-4323000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-30784000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-26424000	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.48
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.45
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.48
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.45
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	63886000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	58824000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	63886000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	58824000	shares
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-30784000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-26424000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	175000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-185000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0	usd
CY2022Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	-330000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	140000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-917000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	315000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-1102000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-30469000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-27526000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	83391000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	73981000	usd
CY2023Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	17532000	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	22518000	usd
CY2023Q1	avdl	Research And Development Tax Credit Receivable Current ResearchAndDevelopmentTaxCreditReceivableCurrent	2283000	usd
CY2022Q4	avdl	Research And Development Tax Credit Receivable Current ResearchAndDevelopmentTaxCreditReceivableCurrent	2248000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6264000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2096000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	109470000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	100843000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	782000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	839000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1475000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1713000	usd
CY2023Q1	us-gaap	Goodwill Goodwill	16836000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	16836000	usd
CY2023Q1	avdl	Research And Development Tax Credit Receivable Non Current ResearchAndDevelopmentTaxCreditReceivableNonCurrent	1245000	usd
CY2022Q4	avdl	Research And Development Tax Credit Receivable Non Current ResearchAndDevelopmentTaxCreditReceivableNonCurrent	1232000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	10931000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	11322000	usd
CY2023Q1	us-gaap	Assets Assets	140739000	usd
CY2022Q4	us-gaap	Assets Assets	132785000	usd
CY2023Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	20515000	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	37668000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	871000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	960000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	10023000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	7890000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7683000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7334000	usd
CY2023Q1	avdl	Proceeds Received In Advance Of Share Issuance Current ProceedsReceivedInAdvanceOfShareIssuanceCurrent	40000000	usd
CY2022Q4	avdl	Proceeds Received In Advance Of Share Issuance Current ProceedsReceivedInAdvanceOfShareIssuanceCurrent	0	usd
CY2023Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	269000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1941000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	79361000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	55793000	usd
CY2023Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	93139000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	91614000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	638000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	780000	usd
CY2023Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5767000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5743000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	178905000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	153930000	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	488000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	488000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	488000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	488000	shares
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue	5000	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	5000	usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	64478000	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	64478000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	62878000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	62878000	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	644000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	628000	usd
CY2023Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	603215000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	589783000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-616004000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-585220000	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-26026000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-26341000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-38166000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-21145000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	140739000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	132785000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-21145000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-30784000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	315000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	11913000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	16000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	0	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	29000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1522000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-38166000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	78244000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-26424000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1102000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1906000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	0	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	103000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2505000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	55232000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-30784000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-26424000	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	588000	usd
CY2022Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	259000	usd
CY2023Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1873000	usd
CY2022Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	312000	usd
CY2023Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2022Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-4323000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1522000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2505000	usd
CY2023Q1	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	-1000	usd
CY2022Q1	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	669000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	4131000	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2058000	usd
CY2023Q1	avdl	Increase Decrease In Research And Development Tax Credit Receivable IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable	0	usd
CY2022Q1	avdl	Increase Decrease In Research And Development Tax Credit Receivable IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable	19000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	468000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-5613000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	348000	usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	2314000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Noncurrent Assets And Liabilities Net IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet	116000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Noncurrent Assets And Liabilities Net IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet	1667000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-30233000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-34045000	usd
CY2023Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	15295000	usd
CY2022Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	44341000	usd
CY2023Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	10229000	usd
CY2022Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	2090000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	5066000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	42251000	usd
CY2023Q1	avdl	Proceeds Received In Advance Of Share Issuance ProceedsReceivedInAdvanceOfShareIssuance	40000000	usd
CY2022Q1	avdl	Proceeds Received In Advance Of Share Issuance ProceedsReceivedInAdvanceOfShareIssuance	0	usd
CY2023Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	17500000	usd
CY2022Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	11913000	usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	29000	usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	2009000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	34442000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2009000	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	135000	usd
CY2022Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-50000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	9410000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	10165000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	73981000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	50708000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	83391000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	60873000	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	3050000	usd
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	5531000	usd
CY2023Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2022Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	83391000	usd
CY2023Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	17532000	usd
CY2023Q1	avdl	Royalty Financing Quarterly Net Revenue Target RoyaltyFinancingQuarterlyNetRevenueTarget	25000000	usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	11913000	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	19281000	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1749000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	17532000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	24407000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1889000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	22518000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	1000	usd
CY2022Q1	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	304000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Realized Loss DebtSecuritiesAvailableForSaleRealizedLoss	61000	usd
CY2022Q2	avdl	Debt Instrument Convertible Embedded Conversion Feature Increase Decrease DebtInstrumentConvertibleEmbeddedConversionFeatureIncreaseDecrease	5508000	usd
CY2022Q2	avdl	Adjustments To Additional Paid In Capital Adjustments In Fair Value Of Convertible Debt Conversion Feature AdjustmentsToAdditionalPaidInCapitalAdjustmentsInFairValueOfConvertibleDebtConversionFeature	5508000	usd
CY2022Q2	avdl	Debt Instrument Convertible Embedded Conversion Feature Increase Decrease DebtInstrumentConvertibleEmbeddedConversionFeatureIncreaseDecrease	5508000	usd
CY2022Q1	us-gaap	Debt Securities Available For Sale Realized Loss DebtSecuritiesAvailableForSaleRealizedLoss	790000	usd
CY2023Q1	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	672000	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	1019000	usd
CY2023Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	20515000	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	37668000	usd
CY2023Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	93139000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	91614000	usd
CY2023Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	3259000	usd
CY2022Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	2017000	usd
CY2023Q1	avdl	Coupon Interest Expense CouponInterestExpense	1386000	usd
CY2022Q1	avdl	Coupon Interest Expense CouponInterestExpense	1617000	usd
CY2023Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1873000	usd
CY2022Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	312000	usd
CY2018Q1	avdl	American Depository Shares Conversion Ratio AmericanDepositorySharesConversionRatio	92.6956	rate
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q1	avdl	Royalty Financing Quarterly Net Revenue Target RoyaltyFinancingQuarterlyNetRevenueTarget	25000000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-580000	usd
CY2023Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.018
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-4323000	usd
CY2022Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.141
CY2023Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	5384000	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1523000	usd
CY2023Q1	us-gaap	Other Assets Current OtherAssetsCurrent	542000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	10931000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	11322000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	228000	usd
CY2023Q1	avdl	Guarantee Current GuaranteeCurrent	269000	usd
CY2022Q4	avdl	Guarantee Current GuaranteeCurrent	276000	usd
CY2023Q1	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	69000	usd
CY2022Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	69000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6264000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2096000	usd
CY2023Q1	avdl	Operating Lease Right Of Use Asset Contract Manufacturing Noncurrent OperatingLeaseRightOfUseAssetContractManufacturingNoncurrent	10392000	usd
CY2022Q4	avdl	Operating Lease Right Of Use Asset Contract Manufacturing Noncurrent OperatingLeaseRightOfUseAssetContractManufacturingNoncurrent	10686000	usd
CY2023Q1	avdl	Guarantee Noncurrent GuaranteeNoncurrent	433000	usd
CY2022Q4	avdl	Guarantee Noncurrent GuaranteeNoncurrent	495000	usd
CY2023Q1	avdl	Other Noncurrent Receivables OtherNoncurrentReceivables	106000	usd
CY2022Q4	avdl	Other Noncurrent Receivables OtherNoncurrentReceivables	141000	usd
CY2023Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	5709000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	4040000	usd
CY2023Q1	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1581000	usd
CY2022Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1613000	usd
CY2023Q1	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	246000	usd
CY2022Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	473000	usd
CY2023Q1	avdl	Accrued Outsource Contract Costs AccruedOutsourceContractCosts	147000	usd
CY2022Q4	avdl	Accrued Outsource Contract Costs AccruedOutsourceContractCosts	1208000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7683000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7334000	usd
CY2023Q1	avdl	Other Guarantor Obligations Current Carrying Value OtherGuarantorObligationsCurrentCarryingValue	269000	usd
CY2022Q4	avdl	Other Guarantor Obligations Current Carrying Value OtherGuarantorObligationsCurrentCarryingValue	277000	usd
CY2023Q1	avdl	Other Liabilities Miscellaneous Current OtherLiabilitiesMiscellaneousCurrent	0	usd
CY2022Q4	avdl	Other Liabilities Miscellaneous Current OtherLiabilitiesMiscellaneousCurrent	15000	usd
CY2023Q1	avdl	Accrued Interest Current AccruedInterestCurrent	0	usd
CY2022Q4	avdl	Accrued Interest Current AccruedInterestCurrent	1649000	usd
CY2023Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	269000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1941000	usd
CY2023Q1	avdl	Tax Liabilities And Other Noncurrent Liabilities TaxLiabilitiesAndOtherNoncurrentLiabilities	5333000	usd
CY2022Q4	avdl	Tax Liabilities And Other Noncurrent Liabilities TaxLiabilitiesAndOtherNoncurrentLiabilities	5246000	usd
CY2023Q1	us-gaap	Guaranty Liabilities GuarantyLiabilities	434000	usd
CY2022Q4	us-gaap	Guaranty Liabilities GuarantyLiabilities	497000	usd
CY2023Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5767000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5743000	usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-30784000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-26424000	usd
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	63886000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	58824000	shares
CY2023Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2022Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	63886000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	58824000	shares
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.48
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.45
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.48
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.45
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12463000	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	17696000	shares
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0	usd
CY2022Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	-330000	usd

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0001012477-23-000012-index-headers.html	Edgar Link	pending
0001012477-23-000012-index.html	Edgar Link	pending
0001012477-23-000012.txt	Edgar Link	pending
0001012477-23-000012-xbrl.zip	Edgar Link	pending
avdl-20230331.htm	Edgar Link	pending
avdl-20230331.xsd	Edgar Link	pending
exhibit311q12023.htm	Edgar Link	pending
exhibit312q12023.htm	Edgar Link	pending
exhibit321q12023.htm	Edgar Link	pending
exhibit322q12023.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
avdl-20230331_cal.xml	Edgar Link	unprocessable
avdl-20230331_def.xml	Edgar Link	unprocessable
avdl-20230331_lab.xml	Edgar Link	unprocessable
avdl-20230331_pre.xml	Edgar Link	unprocessable
avdl-20230331_htm.xml	Edgar Link	completed
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AVDL
AVADEL PHARMACEUTICALS PLC Stock $avdl

2023 Q2 Form 10-Q Financial Statement

#000101247723000012 Filed on May 04, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AVDL AVADEL PHARMACEUTICALS PLC Stock $avdl

2023 Q2 Form 10-Q Financial Statement

#000101247723000012 Filed on May 04, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AVDL
AVADEL PHARMACEUTICALS PLC Stock $avdl